FDA Clears Roche’s CSF Aβ42/tTau Assay
The Elecsys-based assay could run on 100,000 fully automated diagnostic machines worldwide.
611 RESULTS
Sort By:
The Elecsys-based assay could run on 100,000 fully automated diagnostic machines worldwide.
Feeding taurine to mice and monkeys increased the lifespan of the former and reduced signs of aging in both.
In cognitively unimpaired older adults, some gut bacteria correlated with plaques and tangles, but not neurodegeneration.
Among cognitively healthy people, amyloid load tracked with blood p-tau181 and tangles only in those with high blood GFAP.
Three reviews, two perspectives, and four comments discuss recent advances and opportunities for dementia research.
While memory problems plague some people with lingering COVID symptoms, researchers do not yet understand what is going wrong in their brains.
Safety and cerebrospinal fluid tau data from the six-month Phase 1 trial are now published.
Clearance triggers improvement in downstream markers of inflammation and neurodegeneration—but not in those who started with high tangle burden. (Clue: women.)
NPTX2 binds complement C1q, disrupting signals to microglia to destroy synapses.
Volunteers who practiced daily slow-breathing exercises for a month lowered Aβ42 in their blood; could this diminish the risk of AD?
The protein content of extracellular vesicles sampled from hippocampal interstitial fluid depended on age, sex, and amyloid load.
The p-tau217/tau217 ratio in the cerebrospinal fluid tightly correlated with amyloid, while p-tau205/tau205 best detected neurofibrillary tangles and neurodegeneration.
Cognitively normal older adults with high levels of the biomarker slid quickly toward dementia.
Mis-splicing events produce novel proteins that can be detected in the cerebrospinal fluid of ALS/FTD patients before their symptoms start.
Therapeutics research in the field ended on high hopes that lecanemab’s Phase 3 data would carry this anti-Aβ antibody to regulatory approval in country after country in 2023. This wave drew power from progress in biomarker research; but alas, much work remains to be done.